THE MEDICINES COMPANY
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.
THE MEDICINES COMPANY
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1996-01-01
Address:
Parsippany, New Jersey, United States
Country:
United States
Website Url:
http://www.themedicinescompany.com
Total Employee:
1001+
Status:
Closed
Contact:
(973) 290-6000
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Global Site Tag IPv6 CDN JS Cloudflare Hosting IIS IIS 7 Cookie Consent By Osano Silktide Cookie Consent ASP.NET 2.0 Akamai DNS
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-02-04 | Annovation BioPharma | Annovation BioPharma acquired by The Medicines Company | N/A |
| 2014-04-23 | Tenaxis Medical | Tenaxis Medical acquired by The Medicines Company | N/A |
| 2013-12-04 | Rempex Pharmaceuticals | Rempex Pharmaceuticals acquired by The Medicines Company | 474 M USD |
| 2013-08-05 | ProFibrix | ProFibrix acquired by The Medicines Company | 240 M USD |
| 2012-12-12 | Incline Therapeutics | Incline Therapeutics acquired by The Medicines Company | N/A |
| 2009-12-22 | ApoA-I Milano | ApoA-I Milano acquired by The Medicines Company | N/A |
| 2009-01-13 | Targanta Therapeutics | Targanta Therapeutics acquired by The Medicines Company | 42 M USD |
| 2008-08-05 | Curacyte Discovery GmbH | Curacyte Discovery GmbH acquired by The Medicines Company | N/A |
Investors List
Hanseatic Asset Management
Hanseatic Asset Management investment in Venture Round - The Medicines Company
Biotech Growth
Biotech Growth investment in Venture Round - The Medicines Company
Credit Suisse
Credit Suisse investment in Venture Round - The Medicines Company
Warburg Pincus
Warburg Pincus investment in Venture Round - The Medicines Company
Alta Partners
Alta Partners investment in Venture Round - The Medicines Company
GeneChem
GeneChem investment in Venture Round - The Medicines Company
Moore Capital
Moore Capital investment in Venture Round - The Medicines Company
BancAmerica Robertson Stephens
BancAmerica Robertson Stephens investment in Venture Round - The Medicines Company
Morgan Stanley Venture Partners
Morgan Stanley Venture Partners investment in Venture Round - The Medicines Company
Official Site Inspections
http://www.themedicinescompany.com
- Host name: 104.18.3.191
- IP address: 104.18.3.191
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "The Medicines Company"
Our Company | The Medicines Company - Targanta
Jan 3, 2018 The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics. 3 Jan 2018. The Medicines Company to Present at the …See details»
The Medicines Company - Crunchbase Company Profile & Funding
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The …See details»
Novartis to acquire The Medicines Company for USD 9.7 bn, …
Nov 24, 2019 The offer price represents a premium of approximately 41% over The Medicines Company’s 30-day (to November 22, 2019) volume weighted average price of USD 60.33 and …See details»
Leadership Team | The Medicines Company - targanta.com
Nancye Green leads global communications & information architecture for The Medicines Company (MDCO). A designer and business leader, Nancye has had a storied career …See details»
Company Profile for The Medicines Company | Business Wire
Nov 9, 2018 The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the econom ... Type of …See details»
Company The Medicines Company - MarketScreener.com
Business description: The Medicines Company The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a …See details»
The Medicines Company Enters Into Definitive Agreement
Nov 24, 2019 - The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its …See details»
Company Profile for The Medicines Company - MarketScreener
Nov 9, 2018 The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The …See details»
The Medicines Company - Craft
Jan 6, 2020 The Medicines Company. Financials. Summary Financials. Net income (Q3, 2019)($74.0M) Cash (Q3, 2019)$265.9M EBIT (Q3, 2019)($61.4M) Enterprise value $6.9B. …See details»
Why Novartis Is Buying The Medicines Company For …
Nov 26, 2019 Vasant Narasimhan, MD, MPP, CEO of Novartis, is betting on RNA interference by acquiring The ...[+] Medicines Company. (Photo by ERIC PIERMONT/AFP via Getty Images) AFP via Getty ImagesSee details»
The Medicines Company - PitchBook
Jan 22, 2016 The Medicines Company General Information Description. The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The …See details»
The Medicines Company Company Profile | Parsippany, NJ
Find company research, competitor information, contact details & financial data for The Medicines Company of Parsippany, NJ. Get the latest business insights from Dun & Bradstreet. The …See details»
The Medicines Company to be Acquired by Novartis for $9.7B
Nov 25, 2019 Shares of The Medicines Company have skyrocketed 258.2% so far this year versus flat growth by the industry. The company divested all its marketed products in 2018 to …See details»
The Medicines Company Company Information - Drugs.com
Apr 15, 2015 Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided …See details»
The Medicines Company: Innovating Innovation - Forbes
Mar 11, 2019 The Medicines Company bought the rights to bivalirudin from Biogen in 1997 and reassessed the data for the subset of patients with postinfarction angina (chest pain following …See details»
The Medicines Company Enters Into Definitive Agreement to be
Nov 24, 2019 - The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its …See details»
Novartis agrees $9.7bn deal for US cholesterol drugmaker
Nov 24, 2019 Novartis . has agreed a $9.7bn cash deal to acquire The Medicines Company, betting that the US drugmaker will come good on a new drug designed to control cholesterol …See details»
THE MEDICINES COMPANY (SAN DIEGO), LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for THE MEDICINES COMPANY (SAN DIEGO), LLC of San Diego, CA. ... Get the latest business …See details»
The Medicines Company - Contacts, Employees, Board Members
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective. Search Crunchbase. Start Free Trial . ... New …See details»
Medicines Company, The - Case - Harvard Business School
The company is in the business of "rescuing" drugs that other companies have given up on--i.e., they purchase or license the rights to drugs that other companies have halted development on, …See details»